Positive new Ph III data with Novo Nordisk's Xultophy

Positive new pivotal Phase III data about Xultophy (insulin degludec/liraglutide), formerly known as IDegLira, which is being developed by Danish diabetes care giant Novo Nordisk (NOV: N) as a once-daily therapy for adults with type 2 diabetes, has just been published in Diabetes Care, demonstrating efficacy and tolerability of the drug combination.

In the study, Xultophy showed clear patient benefits including a 1.9% reduction in HbA1c levelversus 0.9% with insulin degludec, weight loss of 2.7kg and low rate of hypoglycemia comparable to insulin degludec.

40% of the people treated with the drug, achieved the HbA1c goal with no confirmed hypoglycemic episodes and with no weight gain, compared to 8.5% of people treated with insulin degludec (p<0.0001).